BioAtla saw the highest growth of 2.99% in patent filings in May and 0.66% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of BioAtla‘s patent filings and grants. Buy the databook here.
BioAtla has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 60% filings and 33% grants. The United States(US), Australia(AU), China(CN), and Spain(ES) patent Office are among the top ten patent offices where BioAtla is filings its patents. Among the top granted patent authorities, BioAtla has 33% of its grants in United States(US), 33% in Spain(ES) and 33% in Israel(IL).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for BioAtla
Patents related to nanomedicine and rare diseases lead BioAtla's portfolio
BioAtla has the highest number of patents in nanomedicine followed by, rare diseases and genomics. For nanomedicine, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Cervical cancer related patents lead BioAtla portfolio followed by gastric cancer, and liver cancer
BioAtla has highest number of patents in cervical cancer followed by gastric cancer, liver cancer, kidney cancer (renal cell cancer), and bladder carcinoma.
For comprehensive analysis of BioAtla's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.